In line with previous studies (36, 37), our results demonstrate that antibody titers of known seromarkers, VCA-IgA and EBNA1-IgA, could not be used to predict the survival of NPC patients accurately. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.